Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose ketamine for postoperative anxiety and depression after laparoscopic total hysterectomy
ChiCTR1900022636Phase 4Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ketamine in anxiety disorder and major depressive disorder (MDD) (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Self-rating depression scale. Planned start May 2019; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR1900022636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022636.